{"name":"MGC Pharmaceuticals d.o.o","slug":"mgc-pharmaceuticals-d-o-o","ticker":"","exchange":"","domain":"","description":"MGC Pharmaceuticals d.o.o is a specialty pharmaceutical company focused on developing and commercializing innovative treatments. The company has a pipeline of five drugs, with a strong emphasis on advancing therapies through clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"CimetrA-1","genericName":"CimetrA-1","slug":"cimetra-1","indication":"Neurological or inflammatory conditions (specific indication not publicly disclosed)","status":"phase_3"},{"name":"CimetrA-2","genericName":"CimetrA-2","slug":"cimetra-2","indication":"Treatment-resistant epilepsy","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ArtemiC","genericName":"ArtemiC","slug":"artemic","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"ArtemiC","genericName":"ArtemiC","slug":"artemic","phase":"marketed","mechanism":"ArtemiC is a cannabis-based pharmaceutical product that delivers cannabinoids for therapeutic effect.","indications":[],"catalyst":""},{"name":"CimetrA-1","genericName":"CimetrA-1","slug":"cimetra-1","phase":"phase_3","mechanism":"CimetrA-1 is a cannabinoid-based therapeutic that modulates endocannabinoid system signaling to produce anti-inflammatory and neuroprotective effects.","indications":["Neurological or inflammatory conditions (specific indication not publicly disclosed)"],"catalyst":""},{"name":"CimetrA-2","genericName":"CimetrA-2","slug":"cimetra-2","phase":"phase_3","mechanism":"CimetrA-2 is a synthetic cannabinoid receptor agonist.","indications":["Treatment-resistant epilepsy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMndPMVU3RHNTTTMyWkJxS2JzY0VhYXlLeU9wZF9Sd1ppdG9Qa3BsZVJTSU5HdkZ5SUZST1JwaGdHRHdSUUN3TzRpU0lmSzBkazY0bjVzQU9tTHBSZ29aRzVIMFlURGV5M3RzWld2Tjh0WHQyVXNsWHhJYmlfeEhWTmpKV0hqaVVJeDN1SUxMbHpoVUYyNjdGY1ZwclBvR3VQMTl5ODZmWGtjRVBJeG5NQXo5UGl4M2tWcGd4d25RM3c?oc=5","date":"2024-02-13","type":"pipeline","source":"PR Newswire","summary":"MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation - PR Newswire","headline":"MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}